Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 13 studies | 29% ± 17% | |
astrocyte | 10 studies | 42% ± 22% | |
adipocyte | 10 studies | 56% ± 20% | |
glutamatergic neuron | 8 studies | 48% ± 20% | |
GABAergic neuron | 7 studies | 46% ± 21% | |
oligodendrocyte precursor cell | 7 studies | 43% ± 19% | |
retinal ganglion cell | 7 studies | 60% ± 18% | |
neuron | 6 studies | 43% ± 15% | |
oligodendrocyte | 6 studies | 40% ± 12% | |
interneuron | 5 studies | 61% ± 18% | |
macrophage | 5 studies | 29% ± 13% | |
fibroblast | 5 studies | 23% ± 4% | |
smooth muscle cell | 5 studies | 19% ± 4% | |
type I pneumocyte | 5 studies | 30% ± 9% | |
granule cell | 4 studies | 36% ± 12% | |
microglial cell | 4 studies | 32% ± 12% | |
cardiac muscle cell | 4 studies | 27% ± 3% | |
epithelial cell | 3 studies | 24% ± 7% | |
pericyte | 3 studies | 33% ± 20% | |
mesothelial cell | 3 studies | 23% ± 6% | |
GABAergic amacrine cell | 3 studies | 27% ± 6% | |
rod bipolar cell | 3 studies | 27% ± 9% | |
hepatocyte | 3 studies | 53% ± 14% | |
endothelial cell of lymphatic vessel | 3 studies | 27% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 5610.79 | 258 / 258 | 100% | 47.62 | 230 / 230 |
brain | 100% | 8508.31 | 2641 / 2642 | 99% | 45.14 | 701 / 705 |
thymus | 100% | 3469.63 | 651 / 653 | 99% | 14.18 | 599 / 605 |
breast | 100% | 7100.10 | 458 / 459 | 99% | 19.58 | 1105 / 1118 |
liver | 100% | 3986.31 | 226 / 226 | 97% | 13.41 | 395 / 406 |
prostate | 100% | 4458.16 | 244 / 245 | 98% | 11.82 | 490 / 502 |
esophagus | 100% | 6388.42 | 1440 / 1445 | 97% | 12.99 | 178 / 183 |
uterus | 100% | 5622.32 | 170 / 170 | 97% | 12.74 | 444 / 459 |
kidney | 99% | 2842.09 | 88 / 89 | 98% | 13.47 | 880 / 901 |
skin | 100% | 4098.78 | 1801 / 1809 | 96% | 13.76 | 455 / 472 |
lung | 99% | 4274.12 | 575 / 578 | 96% | 12.52 | 1107 / 1155 |
stomach | 100% | 4470.33 | 359 / 359 | 94% | 10.95 | 270 / 286 |
bladder | 100% | 7660.81 | 21 / 21 | 94% | 11.63 | 475 / 504 |
intestine | 96% | 5035.34 | 928 / 966 | 93% | 9.52 | 488 / 527 |
ovary | 100% | 7826.69 | 180 / 180 | 88% | 10.16 | 378 / 430 |
pancreas | 83% | 1497.96 | 272 / 328 | 97% | 19.22 | 173 / 178 |
adipose | 100% | 9255.66 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 8550.36 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 13.15 | 80 / 80 |
tonsil | 0% | 0 | 0 / 0 | 100% | 11.75 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.56 | 1 / 1 |
heart | 97% | 4041.76 | 837 / 861 | 0% | 0 | 0 / 0 |
muscle | 97% | 2223.45 | 777 / 803 | 0% | 0 | 0 / 0 |
spleen | 96% | 2001.61 | 232 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 69% | 4.96 | 20 / 29 |
peripheral blood | 10% | 143.17 | 91 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006446 | Biological process | regulation of translational initiation |
GO_0000184 | Biological process | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay |
GO_0045727 | Biological process | positive regulation of translation |
GO_0005829 | Cellular component | cytosol |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005515 | Molecular function | protein binding |
GO_0003723 | Molecular function | RNA binding |
GO_0008494 | Molecular function | translation activator activity |
Gene name | CTIF |
Protein name | CBP80/20-dependent translation initiation factor (Cap binding complex dependent translation initiation factor) CBP80/20-dependent translation initiation factor |
Synonyms | KIAA0427 |
Description | FUNCTION: Specifically required for the pioneer round of mRNA translation mediated by the cap-binding complex (CBC), that takes place during or right after mRNA export via the nuclear pore complex (NPC). Acts via its interaction with the NCBP1/CBP80 component of the CBC complex and recruits the 40S small subunit of the ribosome via eIF3. In contrast, it is not involved in steady state translation, that takes place when the CBC complex is replaced by cytoplasmic cap-binding protein eIF4E. Also required for nonsense-mediated mRNA decay (NMD), the pioneer round of mRNA translation mediated by the cap-binding complex playing a central role in nonsense-mediated mRNA decay (NMD). . |
Accessions | ENST00000634350.1 [O43310-2] ENST00000588345.1 ENST00000587752.5 ENST00000635228.2 [O43310-1] ENST00000382998.8 [O43310-2] ENST00000591387.5 ENST00000634324 ENST00000635283 ENST00000591412.5 ENST00000256413.8 [O43310-1] K7EQS5 ENST00000635367 K7EPK6 ENST00000634755 O43310 K7EQS9 K7EK08 |